精優藥業(00858.HK)全年純利增長30.06%至8328萬港元
格隆匯 6 月 29日丨精優藥業(00858.HK)發佈公告,截至2020年3月31日止年度,公司實現收益7758.4萬港元,同比下降13.04%;公司股東應占溢利8328萬港元,同比增長30.06%;每股基本盈利3.48港仙,不派息。
在收緊監管控制及深化醫療改革政策的推動下,市場動態變化亦為該分類帶來巨大壓力。面對瞬息萬變且競爭激烈的市場環境,除繼續執行去年成功實施的戰略舉措以增加競爭力,獲取市場份額以及捕捉增長新機遇外,管理層迅速採取更為嚴格的措施,通過提高生產效率和降低經營成本來提高盈利能力。通過這些共同努力,該分類得以保持集團主要產品線的收益增長趨勢和穩定的毛利率,尤其是專門用於改善人體抵禦疾病的免疫系統的產品。因此,分類收益略微增加至約7760萬港元(2019年:7580萬港元),而毛利率與去年水平相若。
核數師將於獨立核數師報告內就集團截至2020年3月31日止年度的綜合財務報表出具一份保留意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.